WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 584654
Description: M 16209 has been found to be an antidiabetic agent due to amelioration of insulin resistance in peripheral tissues.
MedKoo Cat#: 584654
Name: M 16209
Chemical Formula: C11H7BrN2O5S
Exact Mass: 357.9259
Molecular Weight: 359.15
Elemental Analysis: C, 36.79; H, 1.96; Br, 22.25; N, 7.80; O, 22.27; S, 8.93
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: M 16209; M-16209; M16209
IUPAC/Chemical Name: 2,4-Imidazolidinedione, 1-((3-bromo-2-benzofuranyl)sulfonyl)-
InChi Key: ZJSUDHQFSBHLDV-UHFFFAOYSA-N
InChi Code: InChI=1S/C11H7BrN2O5S/c12-9-6-3-1-2-4-7(6)19-10(9)20(17,18)14-5-8(15)13-11(14)16/h1-4H,5H2,(H,13,15,16)
SMILES Code: O=C1NC(CN1S(=O)(C2=C(Br)C3=CC=CC=C3O2)=O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
The following data is based on the product molecular weight 359.15 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Murakami N, Ohta M, Kato K, Nakayama K, Mizota M, Miwa I, Okuda J. Effects of 1-(3-bromobenzofuran-2-ylsulfonyl)hydantoin on human aldose reductase examined by a new application of HPLC system for measuring tissue polyol. Arzneimittelforschung. 1997 Nov;47(11):1222-5. PubMed PMID: 9428978.
2: Ohta M, Murakami N, Kato K, Mizota M, Miwa I, Okuda J, Yoshimasa Y, Kuzuya H, Nakao K, Imura H. Effects of M16209, a new antihyperglycemic agent, on insulin sensitivity in vivo: euglycemic clamp studies in rats. Metabolism. 1996 Sep;45(9):1095-100. PubMed PMID: 8781296.
3: Kato K, Nakayama K, Mizota M, Miwa I, Okuda J. Properties of novel aldose reductase inhibitors, M16209 and M16287, in comparison with known inhibitors, ONO-2235 and sorbinil. Chem Pharm Bull (Tokyo). 1991 Jun;39(6):1540-5. PubMed PMID: 1934175.
4: Kato K, Nakayama K, Ohta M, Murakami N, Murakami K, Mizota M, Miwa I, Okuda J. Effects of novel hydantoin derivatives with aldose reductase inhibiting activity on galactose-induced cataract in rats. Jpn J Pharmacol. 1990 Dec;54(4):355-64. PubMed PMID: 2128352.
5: Nakayama K, Murakami N, Ohta M, Kato K, Notsu T, Mizota M, Miwa I, Okuda J. Effects of M16209 on insulin secretion in isolated, perfused pancreases of normal and diabetic rats. Eur J Pharmacol. 1995 Mar 24;276(1-2):85-91. PubMed PMID: 7781699.
6: Kato K, Nakayama K, Ohta M, Murakami N, Murakami K, Mizota M, Miwa I, Okuda J. Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats. Eur J Pharmacol. 1991 Feb 7;193(2):185-91. PubMed PMID: 1828768.
7: Murakami N, Inoue G, Okamoto M, Yoshimasa Y, Kohno S, Hayashi T, Kato K, Kuzuya H, Nakao K. Antihyperglycemic mechanism of M16209, an antidiabetic agent, in 3T3-L1 adipocytes. Life Sci. 1997;60(20):1821-31. PubMed PMID: 9150422.
8: Nakayama K, Murakami N, Ohta M, Kato K, Ida K, Mizota M, Miwa I, Okuda J. Antihyperglycemic effects of M16209, a novel aldose reductase inhibitor, in normal and diabetic rats. Eur J Pharmacol. 1995 Mar 24;276(1-2):77-83. PubMed PMID: 7781698.
9: Murakami N, Ohta M, Hashimoto K, Kato K, Mizota M, Miwa I, Okuda J, Inoue G, Kuzuya H, Nakao K, Imura H. Amelioration of insulin resistance in genetically obese rodents by M16209, a new antidiabetic agent. Eur J Pharmacol. 1996 May 23;304(1-3):129-34. PubMed PMID: 8813594.
10: Hashimoto K, Murakami N, Ohta M, Kato K, Mizota M, Miwa I, Okuda J. Acceleration of glycolysis in erythrocytes by the antidiabetic agent M16209. Biol Pharm Bull. 1996 Jun;19(6):809-13. PubMed PMID: 8799477.